Application of cobratide preparation in preparation of medicine for treating postherpetic neuralgia

A technology for postherpetic neuralgia and herpes zoster, which can be used in drug combinations, nervous system diseases, antiviral agents, etc., and can solve problems that have not been reported

Active Publication Date: 2020-04-10
云南南诏药业有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, the role of cobotide in the treatment of postherpetic neuralgia has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cobratide preparation in preparation of medicine for treating postherpetic neuralgia
  • Application of cobratide preparation in preparation of medicine for treating postherpetic neuralgia

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0017] Experimental Example 1 Experimental Study on Pharmacodynamic Evaluation and Mechanism Analysis of Cobotide Preparations in Treating Postherpetic Neuralgia

[0018] 1. Test material

[0019] Group 1: Cobotide injection on the market, provided by Yunnan Nanzhao Pharmaceutical Co., Ltd., specification: 2ml: 70μg; usage and dosage: intramuscular injection, 4ml each time, twice a day, and the injection time should be more than 6 hours .

[0020] Group 2: Cobotide oral tablets, made according to the existing disclosed technical scheme, specifications 280μg / 0.25g tablet; usage and dosage: 1 tablet each time, once a day.

[0021] Group 3: Cobotide enteric-coated tablets, made according to the existing disclosed technical scheme, specifications: 280 μg / 0.25g / vegetarian tablet, usage and dosage: 1 tablet per day, once a day.

[0022] Group 4: Cobotide rectal administration suppository, made according to the existing disclosed technical scheme, specification: 140 μg / 2g supposito...

experiment example 2

[0040] Experimental Example 2 Animal Toxicity Test

[0041] 80 SPF grade SD rats, male and female half and half, body weight 180-220g; divided into 8 groups, each group of 5 male and female; according to the administration method of experimental group 1-5 and matched group 1-3 in experimental example 1 medicine. Continuously administered for 30 days, during the period of administration and 5 days after drug withdrawal, the growth status and activity diet of the mice were observed, and the hematology, blood biochemistry, organ tissue structure and urine routine were identified. The results showed that all SD rats survived healthy without any side effects; the anatomical observations of blood, liver function, and the state of various organs and tissues showed no difference compared with normal SD rats. Experiments have proved that the cobotide preparation provided by the present invention is safe and reliable for administration.

[0042] 3. Conclusion

[0043] Postherpetic ne...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to an application of a cobratide preparation in preparation of a medicine for treating postherpetic neuralgia. The cobratide which is a main component of the cobratide preparation is neurotoxin protein separated and purified from cobra venom, and the content of the neurotoxin protein is not less than 35.0 percent according to a dry product; the preparation is an injection, anoral preparation, an enteric preparation, a rectal administration preparation, an oral absorption preparation and the like. The cobratide preparation has the advantages that the Wallerian degeneration, dehydration, cystic degeneration and ganglion neuronal cell quantity of spinal cord posterior root ganglion caused by herpes zoster viruses are obviously reduced; crude nerve fiber axons of the myelin sheath are reduced and obviously collagenated, and intense neuropathic pain caused by chronic inflammatory cell infiltration in posterior root ganglion of spinal cord is exact in curative effect and good in safety. Besides, the animal experiments prove that the preparation has a quick curative effect on treating postherpetic neuralgia related diseases, has no toxic or side effect, and providesanother choice for patients.

Description

technical field [0001] The invention relates to the technical field of drug application, in particular to the application of cobotide preparations in the preparation of drugs for treating postherpetic neuralgia. Background technique [0002] Herpes zoster is an acute inflammatory skin disease caused by varicella zoster virus (VZV). It is commonly known as "snake pill" and "waisted dragon" among the people, and belongs to the category of "waisted fire pill" and "snake string sore" in traditional Chinese medicine. . In addition to the typical skin herpes, neuralgia is another major feature of this disease. Generally, neuralgia occurs 2-3 days before and after the appearance of the rash, and the degree of pain varies, and has no certain relationship with the severity of the rash. [0003] At present, the pathogenesis of postherpetic neuralgia (PHN) has not been fully elucidated, but it is recognized that the occurrence of acute herpes zoster is closely related to the reductio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P25/02A61P31/22
CPCA61K38/1703A61P25/02A61P31/22Y02A50/30
Inventor 窦啟玲窦雅琪李泽京杨瑶
Owner 云南南诏药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap